MAGE-A4ᶜ¹º³²T for Multi-Tumour

Official Title

Phase 1 Dose Escalation, Multi-tumour Study to Assess the Safety, Tolerability and Antitumour Activity of Genetically Engineered MAGE-A4ᶜ¹º³²T in HLA-A2+ Subjects With MAGE-A4 Positive Tumours

Summary:

This study will investigate the safety and tolerability of MAGE-A4ᶜ¹º³²T cell therapy in subjects who have the appropriate HLA-A2 tissue marker and whose urinary bladder, melanoma, head and neck, ovarian, non-small cell lung, esophageal, gastric, synovial sarcoma, or myxoid/round call liposarcoma (MRCLS) tumour has the MAGE-A4 protein expressed. This study will take a subject's T cells and give them a T cell receptor protein that recognizes and attacks the tumours.

Trial Description

Primary Outcome:

  • Number of subjects with adverse events (AE), including serious adverse events (SAEs).
  • Determining dose limiting toxicities (DLT) and optimally tolerated dose range
  • Evaluation of persistence of genetically modified T cells.
  • Measurement of RCL in genetically modified T cells.
Secondary Outcome:
  • Proportion of subjects with a confirmed Complete Response (CR) and/or Partial Response (PR).
  • Interval between the date of first T cell infusion dose and first documented evidence of CR or PR.
  • Interval between the date of first documented evidence of CR or PR until first documented disease progression or death due to any cause.
  • Interval between the date of first documented evidence of stable disease (SD) until first documented disease progression or death due to any cause.
  • Interval between the date of first T cell infusion and the earliest date of disease, progression or death due to any cause
  • Interval between the date of first T cell infusion and date of death due to any cause.

View this trial on ClinicalTrials.gov

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.

Resources

Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society